Detection of hematogenous bone metastasis in cervical cancer

BACKGROUND: In this large‐scale, retrospective study, the authors evaluated the diagnostic performances of computed tomography (CT), magnetic resonance (MR) imaging, and 18F‐fluorodeoxyglucose‐positron emission tomography (18F‐FDG–PET) in detecting hematogenous bone metastasis in patients with cervi...

Full description

Saved in:
Bibliographic Details
Published inCancer Vol. 115; no. 23; pp. 5470 - 5480
Main Authors Liu, Feng‐Yuan, Yen, Tzu‐Chen, Chen, Min‐Yu, Lai, Chyong‐Huey, Chang, Ting‐Chang, Chou, Hung‐Hsueh, Hong, Ji‐Hong, Chen, Yu‐Ruei, Ng, Koon‐Kwan
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.12.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND: In this large‐scale, retrospective study, the authors evaluated the diagnostic performances of computed tomography (CT), magnetic resonance (MR) imaging, and 18F‐fluorodeoxyglucose‐positron emission tomography (18F‐FDG–PET) in detecting hematogenous bone metastasis in patients with cervical cancer. The associated risk factors also were analyzed. METHODS: Patients with invasive cervical cancer who had both 18F‐FDG–PET studies and CT or MR imaging studies were selected. Patients who had either International Federation of Gynecology and Obstetrics (FIGO) stage III/IV disease or positive lymph node metastasis at the time of primary staging and patients who had suspected recurrent disease were included in the analyses. The diagnostic performances of PET was compared with the performance of CT and MR imaging by using the area under the receiver‐operating‐characteristic curve (AUC). Both univariate and multivariate analyses were applied to assess the risk factors for hematogenous bone metastasis at primary staging. RESULTS: PET was more sensitive than CT (P = .004) and was more specific than MR imaging (P = .04). The diagnostic performance of PET was significantly superior to the performance CT (AUC, 0.964 vs 0.662; P < .001) and MR (AUC, 0.966 vs 0.833; P = .033). Both FIGO stage and the extent of lymph node metastases were associated with hematogenous bone metastasis in univariate analysis. However, the extent of lymph node metastases was the only significant risk factor in multivariate analysis (P = .025). CONCLUSIONS: The current study demonstrated the superiority of 18F‐FDG–PET over CT and MR imaging for detecting hematogenous bone metastasis in patients with advanced cervical cancer. Hematogenous bone metastasis in cervical cancer was associated with the extent of lymph node metastases rather than with FIGO stage. Cancer 2009. © 2009 American Cancer Society. The current study demonstrated the superiority of 18F‐fluorodeoxyglucose–positron emission tomography over computed tomography and magnetic resonance imaging for detecting hematogenous bone metastasis in patients with advanced cervical cancer. Hematogenous bone metastasis in cervical cancer was associated strongly with the extent of lymph node metastases rather than with International Federation of Gynecology and Obstetrics stage.
Bibliography:Koon‐Kwan Ng and Tzu‐Chen Yen contributed equally to this work.
Fax: (011) 886‐3‐2110052
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.24599